Nord-Trondelag Hospital Trust

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Crohn's disease1 trial
• Immune thrombocytopenia (ITP)1 trial
• Multiple myeloma1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• AbbVie1 trial
• Norwegian University of Science and Technology1 trial
• Norwegian University Of Science And Technolology1 trial
• Oslo University Hospital1 trial
• Ostfold Hospital Trust1 trial
• and 1 more

Running trials

• Recruiting

  Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study

  2023-505573-32-00· Phase 3· Ostfold Hospital Trust· Source

• Active, not recruiting

  Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?

  NCT05223647· Phase 3· Norwegian University Of Science And Technolology· Source

• Recruiting

  The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

  NCT04513639· Phase 2/3· Oslo University Hospital· Source

• Active, not recruiting

  Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

  NCT03540420· Phase 2· Norwegian University of Science and Technology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Immune thrombocytopenia (ITP)1 recruiting

Closed trials

• Recruiting

  Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

  NCT05344209· Phase 2· Vestre Viken Hospital Trust· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source